Characterising the molecular interactions in the CTLA-4 and PD-1 pathways as a basis for novel strategies in immune checkpoint blockade
Characterising the molecular interactions in the CTLA-4 and PD-1 pathways as a basis for novel strategies in immune checkpoint blockade
批准号:
2410685
负责人:
金额:
$0.0万
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --
中文摘要
免疫疗法彻底改变了癌症的治疗方法。2018年诺贝尔医学奖授予Allison和Honjo,他们承认了我们癌症治疗方法的这一突破性转变,即使用抗体来解除免疫系统的“刹车”,而不是针对癌症组织的细胞毒药物。这种针对免疫系统而不是癌症的目标代表了思维的根本变化,认识到免疫系统可以针对癌症,因此操纵免疫反应可以非常有益。到目前为止,目标的两个主要检查点是CTLA-4和PD-1通路,这两个通路分别被单独和越来越多地结合在一起。尽管对这些途径进行了20多年的研究,但我们对这些途径的实际工作原理仍然知之甚少。此外,现在还发现,这些途径之间在分子水平上存在明显的生物物理相互作用,但尚未得到适当的表征。桑索姆实验室在这一领域取得了重大进展,他们发现CTLA-4具有捕获和破坏其配体(CD80和CD86)的非凡能力,这种能力使用一种称为内吞细胞作用(TE)的细胞生物学过程,为我们的研究提供了一个平台。由于CTLA-4不寻常的细胞生物学涉及细胞内递送到受限的免疫突触、快速内化、循环和降解,CTLA-4抗体靶向的最佳策略尚未确定。最近的数据还显示,CTLA-4的一个配体(CD80)也直接与PD-1途径的一个配体(PD-L1)相互作用。当考虑抗体调节时,这会产生许多额外的情况。例如,CTLA-4的表达水平可能通过控制CD80的可用性,直接调节PD-L1-PD-1途径。因此,拟议的项目将探索操纵这些检查点的不同策略,包括在CTLA-4和PD-1途径中单独和联合使用多种抗体配方(高亲和力与低亲和力、封闭与非封闭、不同Fc区域和不同大小(Fab2、Fab‘、Fv等))的影响。该项目将在分子水平(结合、解离、运输、降解影响)和细胞水平(免疫调节、T细胞活性、ADCC等)评估影响。以便更好地理解、操纵和预测它们在治疗方案中的使用。总体而言,该项目将提供关于免疫检查站生物学的重点培训,以及与抗体工程相关的制药业的直接经验。提供有关合作伙伴研究方面的培训,包括使用纯化的蛋白质测量其生物物理特性,以及基因操纵的细胞系和原代人类细胞的功能影响。2)。探索设计能够调节上述相互作用并确定其作用模式的新蛋白质(抗体变异体、可溶性模拟物、配基突变体)。通过CD80与PD-L1的相互作用,确定内吞过程对PD-1途径调控的影响)。表征临床上可用的抗CTLA-4和抗PD-L1抗体影响上述过程的能力,并将它们与本计划中产生的新变体进行比较。由于CTLA-4和PD-1通路都影响癌症生物学,并且是常见自身免疫性疾病的关键控制点,因此对这些通路的分子细节的理解以及如何在治疗上最好地操纵它们与疾病主题的基本机制高度相关。
英文摘要
Immunotherapy has revolutionised the treatment of cancer. The 2018 Nobel Prize in medicine to Allison and Honjo recognised this groundbreaking shift in our approach to cancer treatment whereby instead of cytotoxic drugs targeting cancer tissue, antibodies are used to remove the "brakes" on the immune system. This targeting of the immune system and not the cancer represents a fundamental change in thinking, recognising that cancer can be targeted by the immune system and therefore manipulating the immune response can be highly beneficial.The two main checkpoints targeted to date have been the CTLA-4 and PD-1 pathways, which have been targeted both separately and increasingly together. Despite over two decades of research into these pathways we still understand remarkably little about how these pathways actually work. In addition, it is now emerging that there are clear biophysical interactions between these pathways at the molecular level which have yet to be properly characterised. The Sansom lab has made significant progress in this area by identifying that CTLA-4 has the remarkable ability to capture and destroy its ligands (CD80 and CD86) using a cell biological process known as Transendocytosis(TE) providing a platform for our studies. Because of the unusual cell biology of CTLA-4 involving intracellular delivery to a confined immune synapse, rapid internalisation, recycling and degradation the best strategies for antibody targeting of CTLA-4 have yet to be determined.Recent data has also revealed that one of the CTLA-4 ligands (CD80) also directly interacts with a ligand from the PD-1 pathway (PD-L1). This produces numerous additional scenarios when considering antibody modulation. For example, it is likely that the level of CTLA-4 expression, by controlling the availability of CD80, directly regulates the PD-L1- PD-1 pathway. The proposed project will therefore explore different strategies for manipulating these checkpoints including the impact of multiple formulations of antibodies (high affinity vs low affinity, blocking vs non-blocking, different Fc regions and different sizes (Fab2, Fab', Fv, etc) used alone alone and in combination within the CTLA-4 and PD-1 pathways. The project will evaluate impacts at both the molecular level (binding, dissociation, trafficking, degradation effects) and cellular levels (immune modulation, T cell activity, ADCC etc.) in order to better understand, manipulate and predict their use in treatment scenarios. Overall the project will provide a focused training on the biology of immune checkpoints as well as direct experience of the pharmaceutical industry relating to antibody engineering.In this project we therefore aim to:1). Provide training in the study of the relevant partners involved, including measurement of their biophysical characteristics using purified proteins and functional impacts genetically manipulated cell lines and primary human cells. 2). Explore the design of new proteins (antibody variants, soluble mimics, ligand mutants) that can act to modulate the above interactions and determine their mode of action.3). Determine the influence of transendocytosis process on the regulation of the PD-1 pathway via CD80 interaction with PD-L1.4). Characterise the impact of clinically available anti-CTLA-4 and anti-PD-L1 antibodies for their ability to influence the above processes and compare them with novel variants produced in this programme.Since both the CTLA-4 and PD-1 pathways affect cancer biology and are key control points for common autoimmune diseases, the understanding of these pathways in molecular detail and how to best manipulate them therapeutically is highly relevant to the fundamental mechanisms of disease theme.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
-
批准号:82370981
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:陈敏洁
-
依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
-
批准号:82372073
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张淼
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
-
批准号:82372328
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:项盈
-
依托单位:
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
-
批准号:82304565
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:李瑾
-
依托单位:
Irisin通过整合素调控黄河鲤肌纤维发育的分子机制研究
-
批准号:32303019
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:职韶阳
-
依托单位:
转录因子LEF1低表达抑制HMGB1致子宫腺肌病患者子宫内膜容受性低下的分子机制
-
批准号:82371704
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:徐步芳
-
依托单位:
上皮细胞黏着结构半桥粒在热激保护中的作用机制研究
-
批准号:31900545
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:傅容
-
依托单位: